These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 11764451)

  • 1. [Compliance with treatment in schizophrenia and mood disorders].
    Sorvaniemi M; Kampman O
    Duodecim; 2000; 116(3):277-84. PubMed ID: 11764451
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of schizophrenia with substance use disorders.
    Lybrand J; Caroff S
    Psychiatr Clin North Am; 2009 Dec; 32(4):821-33. PubMed ID: 19944886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The problem of drug compliance in schizophrenic patients].
    Albus M
    Psychiatr Prax; 1995 Nov; 22(6):221-2. PubMed ID: 8570750
    [No Abstract]   [Full Text] [Related]  

  • 5. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prototype approach toward antipsychotic medication adherence in schizophrenia.
    Freudenreich O; Tranulis C
    Harv Rev Psychiatry; 2009; 17(1):35-40. PubMed ID: 19205965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.
    Roth BL; Sheffler DJ; Kroeze WK
    Nat Rev Drug Discov; 2004 Apr; 3(4):353-9. PubMed ID: 15060530
    [No Abstract]   [Full Text] [Related]  

  • 8. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.
    Potvin S; Stip E; Lipp O; Roy MA; Demers MF; Bouchard RH; Gendron A
    Am J Drug Alcohol Abuse; 2008; 34(1):75-82. PubMed ID: 18161645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Compliance in therapy of schizophrenic patients with neuroleptics--an overview].
    Mayer C; Soyka M
    Fortschr Neurol Psychiatr; 1992 Jun; 60(6):217-22. PubMed ID: 1353747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders.
    Awad AG
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):1-4. PubMed ID: 20121558
    [No Abstract]   [Full Text] [Related]  

  • 12. [Compliance].
    Vandel P
    Encephale; 2007 Jun; 33 Pt 3():S399-401. PubMed ID: 19101359
    [No Abstract]   [Full Text] [Related]  

  • 13. Insight and adherence to treatment in psychotic disorders.
    Kemp RA; David AS
    Br J Hosp Med; 1995 Sep 6-19; 54(5):222-7. PubMed ID: 8528530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
    Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Canive JM; Miller DD; Reimherr F; McGee M; Khan A; Van Dorn R; Rosenheck RA; Lieberman JA
    J Nerv Ment Dis; 2006 Mar; 194(3):164-72. PubMed ID: 16534433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of psychotropic drugs in the insidious deconstruction of the Kraepelinian dichotomy.
    Vinar O
    Psychiatr Danub; 2007 Dec; 19(4):354-8. PubMed ID: 18000488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia and comorbid substance use disorder: effects of antipsychotics.
    Green AI
    J Clin Psychiatry; 2005; 66 Suppl 6():21-6. PubMed ID: 16107180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders.
    Jónsdóttir H; Friis S; Horne R; Pettersen KI; Reikvam A; Andreassen OA
    Acta Psychiatr Scand; 2009 Jan; 119(1):78-84. PubMed ID: 18983630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Compliance in the treatment of schizophrenia--project ADHES (the renewed results)].
    Chadzyńska M; Meder J; Tyszkowska M
    Psychiatr Pol; 2008; 42(4):561-70. PubMed ID: 19189600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J; Bitter I
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.